Good morning, everyone, and how are you today? We survived our televsion taping last night, thank you very much, and are now preparing for yet another busy day. 'Tis the middle of the week, after all. Our agenda includes hosting a webinar at 1 pm EST on specialty pharma, benefits and co-pays (
please look here). As always, there is much to do, so no need to dilly dally. Grab a cup of stimulation and peruse the tidbits. Hope your day goes well and keep us in mind if you hear something fascinating...
Pharmacyclics Given Breakthrough Status For Cancer Drug (Bloomberg News)
UK's NICE Rejects Novartis Blood Cancer Drug (Reuters)
Reckitt Benckiser Pays $482M For Bristol-Myers OTC Drugs (Pharma Times)
After Failed Trials, J&J Turns To Early Stage Alzheimer's (Reuters)
Connecticut Legislators Push Bill To Attract Biopharma (The Day)
Glaxo And Other Big Drugmakers Vye For Brazil's Ache Labs (Reuters)
Sanofi Expands Investment In Genzyme Plant In Ireland (Pharma Times)
Merck And Lycera Autoimmune Disorder Develpment Deal (BioWorld)
EDITOR'S NOTE: Please check this post for additional items during the day
bagel and cappucino pic thx to magnusd on flickr